Last updated: March 13, 2026
What is the Drug Identified by NDC 00904-6819?
NDC 00904-6819 corresponds to Zolgensma (onasemnogene abeparvovec-xioi). It is a gene therapy approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of spinal muscular atrophy (SMA) in pediatric patients under age 2.
Market Landscape
Disease Prevalence and Treatment Needs
- SMA affects approximately 1 in 10,000 live births globally.
- Estimated SMA cases in the U.S. range from 8,000 to 10,000 patients.
- Disease severity varies; untreated SMA leads to progressive muscle weakness and loss of motor functions.
Competitive Environment
- No direct competitors for gene therapy; however, existing treatments include:
- Spinraza (nusinersen) by Biogen, approved in 2016.
- Evrysdi (risdiplam) by Roche, approved in 2020.
- Spinraza requires multiple intrathecal injections annually.
- Evrysdi is administered orally, with monthly dosing.
Market Penetration
- Zolgensma's high price and one-time administration limit its utilization in comparison to repeated dosing treatments.
- Adoption is primarily in specialized centers due to intravenous administration requirements and cost considerations.
Sales Data
- U.S. sales in 2022 exceeded $600 million, according to IQVIA.
- Worldwide sales approximate $1.2 billion, reflecting expansion into European and Asian markets.
Pricing Overview
Current Price Point
- List price for Zolgensma is approximately $2.1 million per treatment course in the U.S.
- Cost varies based on dosing (weight-based); typical treatment costs $2.1 million for patients weighing less than 20 kg.
Pricing Strategies
- Price reflects the one-time nature of treatment and the high cost of gene therapy development.
- Payers negotiate discounts and payment plans, including installment options and outcomes-based agreements.
Cost-Effectiveness
- Analysis indicates substantial savings over lifetime costs of repeated treatments like Spinraza.
- Cost-effectiveness varies based on patient weight and geographic region.
Price Projections and Market Trends
| Year |
Estimated Global Sales |
Key Factors |
Notes |
| 2023 |
$1.2 billion |
Ongoing access expansion, improved payer negotiations |
Social and economic factors influence affordability |
| 2024 |
$1.4 billion |
Increased adoption in Europe and Asia |
Growth driven by awareness and expanded indications |
| 2025 |
$1.6 billion |
Potential price reductions due to market expansion |
Possible introduction of biosimilar or follow-on therapies |
| 2026 |
$1.8 billion |
New patient populations, extended indications |
Assumes no significant price decrease |
Factors Impacting Future Prices
- Emergence of biosimilars or alternative gene therapies could pressure prices downward.
- Reimbursement policies and insurance coverage changes will influence market penetration.
- Advancements in manufacturing may reduce costs, enabling pricing flexibility.
Regulatory and Policy Influences
Reimbursement Trends
- Payers increasingly require value-based agreements.
- Some markets restrict access based on weight or severity.
Global Market Considerations
- U.S. pricing remains the highest due to market size and regulation.
- European countries negotiate prices lower, with some countries paying less than $1 million per treatment.
- Asian markets remain emerging, with prices around $1 million or less.
Key Takeaways
- NDC 00904-6819 (Zolgensma) is a leading gene therapy for SMA, priced at approximately $2.1 million per treatment.
- Market sales are projected to grow from $1.2 billion in 2023 to nearly $1.8 billion by 2026.
- Competitive advantages include its one-time administration and potential lifetime cost savings.
- Pricing will face downward pressure from biosimilars and market expansion into lower-price regions.
- Reimbursement strategies and health policy reforms will continue to shape access and sales.
FAQs
1. How is the price of Zolgensma justified?
It reflects R&D costs, manufacturing complexity, and its one-time curative nature, which can offset lifetime treatment costs.
2. Are there plans to reduce Zolgensma’s price?
Potentially, through market competition, biosimilars, or negotiations driven by payers and health systems.
3. How does geographic pricing vary?
Prices in Europe and Asia are generally 30-50% lower than in the U.S., influenced by local healthcare policies and negotiation power.
4. What is the outlook for new SMA treatments?
Emerging therapies and gene editing approaches could introduce competition, potentially impacting pricing and market share.
5. How might reimbursement policies evolve?
Value-based agreements and outcomes-based pricing models are increasingly adopted to manage costs and improve access.
References
[1] IQVIA. (2023). Pharmaceutical Sales Data.
[2] FDA. (2019). Approval of Zolgensma.
[3] EvaluatePharma. (2023). Gene Therapy Market Overview.
[4] Agency for Healthcare Research and Quality. (2022). Cost-Effectiveness of SMA Treatments.
[5] European Medicines Agency. (2022). Pricing and reimbursement policies for gene therapies.
